Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Ethics in Research01:56

Ethics in Research

Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Human deskilling in medical artificial intelligence: prohibited or permissible under the EU Artificial Intelligence Act?

Nature reviews. Gastroenterology & hepatology·2026
Same author

eConsent vs traditional consent among prospective biobank participants: a randomized study within a study trial.

npj digital public health·2026
Same author

Digital Twins in Translational Research and Health Care: An Anthropological Perspective.

Ethics & human research·2026
Same author

Utah's Prescription-Renewal Pilot Program - Autonomous AI Managing Patient Care.

The New England journal of medicine·2026
Same author

Medicare advantage becoming a disadvantage with use of artificial intelligence in prior authorization review.

NPJ digital medicine·2026
Same author

Competition in human genetic technologies: The current US legal landscape.

American journal of human genetics·2026

相关实验视频

Updated: Jun 18, 2026

Barnes Maze Testing Strategies with Small and Large Rodent Models
12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 27, 2014

美国食品和药物管理局计划逐步淘汰动物试验.

Sara Gerke1, Jacob Balamut2, Jennifer K Wagner3

  • 1College of Law and European Union Center, University of Illinois Urbana-Champaign, Champaign, IL, USA.

Trends in biotechnology
|January 22, 2026
PubMed
概括

新方法方法提供更便宜,更安全的药物,没有动物试验. 仔细实施是关键,正如我们与FDA讨论的那样.

关键词:
美国食品药品监督管理局 FDA FDA美国食品和药物管理局现代化法案2.0和3.0这些是NAMs.新方法方法论新方法方法论动物试验动物试验.

更多相关视频

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
04:28

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals

Published on: March 23, 2016

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
02:44

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

相关实验视频

Last Updated: Jun 18, 2026

Barnes Maze Testing Strategies with Small and Large Rodent Models
12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 27, 2014

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
04:28

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals

Published on: March 23, 2016

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
02:44

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

科学领域:

  • 药理学和毒理学 药理学和毒理学
  • 生物技术是生物技术.
  • 监管科学 监管科学

背景情况:

  • 药物开发的传统动物试验面临着伦理和效率方面的挑战.
  • 新方法方法 (NAM) 正在成为动物试验的替代品.
  • 人们对NAM在监管过程中的步伐和谨慎实施存在担忧.

研究的目的:

  • 探索 NAM 开发更安全,更具成本效益的药物的潜力.
  • 讨论FDA现代化法案2.0和3.0的含义.
  • 概述美国食品和药物管理局 (FDA) 减少并最终取代动物试验的战略.

主要方法:

  • 对新方法方法论的当前文献的综述.
  • 对立法框架的分析,包括FDA现代化法案2.0和3.0.
  • 审查FDA关于逐步淘汰动物试验的战略路线图.

主要成果:

  • NAMs为药物开发提供了一个有希望的途径,有可能减少痛苦和成本.
  • 立法方面的进展标志着药物安全性评估中转向替代方法的转变.
  • 美国食品和药物管理局 (FDA) 正在积极制定一项路线图,以从动物试验过渡到动物试验.

结论:

  • 谨慎和深思熟虑地实施NAM对于成功开发药物至关重要.
  • 像FDA这样的监管机构正在为减少对动物试验的依赖铺平道路.
  • 药物安全性评估的未来包括整合创新的非动物试验方法.